Navigation Links
Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
Date:6/13/2012

SUNNYVALE, Calif., June 13, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Wells Fargo Healthcare Conference in Boston on Wednesday June 20, 2012 at 9:00 a.m. EDT/6:00 a.m. PDT. 

A live webcast of the presentations will be available online from the Investor Relations page of the Company's website at http://www.accuray.com.  The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately 30 days.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
2. Accuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
3. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
4. Accuray Announces Results for Third Quarter Fiscal 2012
5. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
6. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
7. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
8. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
9. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
10. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
11. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Acsis Inc., ... protection and serialization solutions, has recently posted an ... that addresses current and future needs for companies, ... the old supply chain model no longer work ... technology, including the growth of mobile technology, machine ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2
... WIRE)--Jun 19, 2007 - Javelin,Pharmaceuticals (AMEX: JAV) ... morphine) successfully met its,primary clinical endpoint, the ... over 0-24 hours postoperatively. In this first ... moderate-to-severe pain,after elective orthopedic surgery were given ...
... --,Nuvelo, Inc. today announced the publication of the ... rNAPc2,To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) ... of Cardiology (JACC), demonstrating,that higher-dose (greater than or ... (rNAPc2) reduced the incidence,and duration of ischemia as ...
Cached Medicine Technology:Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 2Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 3Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 4Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4
(Date:7/25/2014)... News) -- Although cervical cancers are declining in the ... papillomavirus (HPV) are increasing, a new study indicates. ... the tongue and tonsils have increased over the past ... 45, the Canadian researchers report. "The increases in ... and of anal cancer among younger women are disturbing, ...
(Date:7/25/2014)... 2014 The Europe Cyber Security report ... Europe with analysis and forecast of revenue. This market ... 2014 to $19.07 billion by 2019, at a CAGR ... the TOC of the Europe Cyber Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:7/25/2014)... American Brain Tumor Association (ABTA) today unveiled branding of ... patient and family conference in Chicago. , “This is ... we – the first and now only national organization ... tumor research – extend our reach by engaging volunteers ... our materials and services into the hands of those ...
(Date:7/25/2014)... Chicago, IL (PRWEB) July 25, 2014 Today, ... brain tumor, and yet, when it comes to pinpointing causes ... “Right now, we don’t know who, we don’t know when, ... Elizabeth M. Wilson, MNA, president & CEO, American Brain Tumor ... why the American Brain Tumor Association funds research to pursue ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... Substrate Wafer, Devices, Applications, and Geography - Analysis & ... by substrate is expected to reach $3.01 Billion by ... Sapphire Technology Market for devices is expected to reach ... that includes an in-depth analysis of application and geography. ...
Breaking Medicine News(10 mins):Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 2Health News:Brain Tumor Causes and Risk Factors Elude Scientists 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6
... exposure causes genetic changes in breast cells , , THURSDAY, ... many plastic products used in households caused accelerated breast ... a condition that might predispose the animals to breast ... Butyl benzyl phthalate (BBP) is commonly used to soften ...
... occurrence in television shows and movies, but can watching it make ... Although research has shown ... there has been little direct neuroscientific support for this theory until ... Researchers at Columbia University Medical Centers Functional ...
... Program Sets Stage for Increased Visibility ... Among Shareholders and Investors, ... EMIS ) announced today that it has retained Adam,Friedman Associates, ... is a biopharmaceutical company that focuses on a,unique and improved ...
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 5th Annual Global Follow-On Biologics,Conference on December 11, 2007 ... be held at the Hyatt Regency Hotel in Reston,Virginia, ... and will bring together corporate, regulatory, financial, and legal,experts ...
... SAN FRANCISCO, Calif., Dec. 6 Proteolix, Inc.,announced ... studies using,intravenous carfilzomib (PR-171) are to be presented ... Meeting in Atlanta, Georgia, December,8-10, 2007. Carfilzomib is ... for the treatment of multiple myeloma,lymphoma and solid ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today details of ... chronic myelogenous leukemia,(CML) at the upcoming American Society of Hematology,s ... 8th - 11th, 2007 in,Atlanta, Georgia., , The schedule ... Date: ...
Cached Medicine News:Health News:Common Household Chemical Could Raise Breast Cancer Risk 2Health News:Common Household Chemical Could Raise Breast Cancer Risk 3Health News:This is your brain on violent media 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: